Metraipolis › archive › dc_7cda8952a9ee

Antibody in Lymphocyte Supernatant (ALS) responses after oral vaccination with live Shigella sonnei vaccine candidates WRSs2 and WRSs3 and correlation with… — Europe PMC PMID:34793505

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/34793505
DOI
10.1371/journal.pone.0259361
License (as archived)
CC0-1.0
Archived
2026-11-01T09:28:40.808Z
SHA-256 of the archived text
22e86ebb55d5ad375b5e4146ce751234907ec0425a101048c0faf9d556714801
Stable URL of this page
https://metraipolis.com/documento/dc_7cda8952a9ee

How to cite

Antibody in Lymphocyte Supernatant (ALS) responses after oral vaccination with live Shigella sonnei vaccine candidates WRSs2 and WRSs3 and correlation with… — Europe PMC PMID:34793505 — Europe PMC (en), https://europepmc.org/article/MED/34793505 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_7cda8952a9ee (Metraipolis archive dc_7cda8952a9ee, sha256 22e86ebb55d5ad375b5e4146ce751234907ec0425a101048c0faf9d556714801)
BibTeX
@misc{dc7cda8952a9ee,
  title = {Antibody in Lymphocyte Supernatant (ALS) responses after oral vaccination with live Shigella sonnei vaccine candidates WRSs2 and WRSs3 and correlation with… — Europe PMC PMID:34793505},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/34793505},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_7cda8952a9ee; sha256 22e86ebb55d5ad375b5e4146ce751234907ec0425a101048c0faf9d556714801},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/34793505. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

The levels of antigen-specific Antibodies in Lymphocyte Supernatant (ALS) using an ELISA are being used to evaluate mucosal immune responses as an alternate to measuring the number of Antibody Secreting Cells (ASCs) using an ELISpot assay. A recently completed trial of two novel S. sonnei live oral vaccine candidates WRSs2 and WRSs3 established that both candidates were safe, well tolerated and immunogenic in a vaccine dose-dependent manner. Previously, mucosal immune responses were measured by assaying IgA- and IgG-ASC in peripheral blood mononuclear cells (PBMCs). In this report, the magnitude of the S. sonnei antigen-specific IgA- and IgG-ALS responses was measured and correlated with previously described ASCs, serum antibodies, fecal IgA and vaccine shedding. Overall, the magnitude of S. sonnei anti-Invaplex50 ALS was higher than that of LPS or IpaB, and both vaccines demonstrated a more robust IgA-ALS response than IgG; however, compared to WRSs3, the magnitude and percentage of responders were higher among WRSs2 recipients for IgA- or IgG-ALS. All WRSs2 vaccinees at the two highest doses responded for LPS and Invaplex50-specific IgA-ALS and 63-100% for WRSs3 vaccinees responded. Regardless of the vaccine candidate, vaccine dose or detecting antigen, the kinetics of ALS responses were similar peaking on days 7 to 9 and returning to baseline by day 14. The ALS responses were vaccine-specific since no responses were detected among placebo recipients at any time. A strong correlation and agreement between responders/non-responders were noted between ALS and other mucosal (ASC and fecal IgA) and systemic (serum antibody) immune responses. These data indicate that the ALS assay can be a useful tool to evaluate mucosal responses to oral vaccination, an observation noted with trials of other bacterial diarrheal pathogens. Furthermore, this data will guide the list of immunological assays to be conducted for efficacy trials in different populations. It is hoped that an antigen-specific-ALS titer may be a key mucosal correlate of protection, a feature not currently available for any Shigella vaccines candidates. https://clinicaltrials.gov/show/NCT01336699.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2021 (prima pubblicazione 2021-11-18).
Identificativi: PMID 34793505 · PMCID PMC8601580 · DOI 10.1371/journal.pone.0259361.
Descrittori MeSH principali: Feces; Shigella sonnei; Immunoglobulin A; Shigella Vaccines; Antibodies, Bacterial.
Pagina: https://europepmc.org/article/MED/34793505 — https://doi.org/10.1371/journal.pone.0259361. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-11-01T09:18:07.833Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.